1. The quality of eggs declines: age is an unavoidable hurdle
As women age, eggs face triple blows:
① Inventory emergency: The loss of primary follicles is accelerating, and ovarian reserves fall like a cliff after the age of 35
② Oxidative damage: Reactive oxygen species (ROS) accumulate in the oocyte, damaging genetic material
③ Energy crisis: Mitochondrial function declines, and egg maturity and division ability drop sharply.
The consequences are directly reflected in test tube data: the aneuploidy rate of embryos in women ≥40 years old exceeds 80%

2. Growth hormone: the underestimated "egg restorer"
Growth hormone (GH) is not a new drug, but its value in the reproductive field has only been deeply explored in recent years. Its mechanism of action is like a twin-engine drive:
④ Direct pathway: GH binds to the growth hormone receptor (GHR) on the surface of theca cells, granulosa cells and oocytes, activating mitochondrial function and reducing ROS damage
▲ Indirect pathway: Stimulate the liver to secrete insulin-like growth factor (IGF-1), which cooperates with gonadotropin to enhance follicular maturity.
Key evidence: A 2015 Spanish study confirmed for the first time that GH pretreatment can increase the euploidy rate of embryos in older women by 40%.

3. Who will benefit most? Clinical data disclosure
Growth hormone is not a "comprehensive drug", but the effect is significant in three groups of people:
① Patients with decreased ovarian function (DOR):
In women with AMH< 1.1 ng/ml and 5 basal follicles<, the rate of high-quality embryos after GH pretreatment was 2.3 times higher
② Patients with repeated poor embryo quality:
Transplantation failure in previous cycles due to high fragmentation rate and delayed division, and the number of normal fertilized eggs (2PN) increased by 68% after GH addition
③ Elderly test tube population ≥35 years old:

4. Plan upgrade: Long-term pretreatment becomes a new trend
Traditional protocols only inject GH simultaneously during the excretion promotion cycle, but recent research shows that:
▲ The 12-week course of treatment (started 8-12 weeks before the promotion) has excellent results:
Case: A 37-year-old patient with DOR experienced 3 failed cycles and was pretreated with GH 2U/day ×8 weeks. The number of oocytes retrieved ranged from 0 to 4, and the pregnancy was finally successful
③ Low doses are safer: 2-4 IU subcutaneous injections per day to avoid side effects such as blood sugar fluctuations and joint pain.

5. Expert consensus: treat it rationally, use medicine scientifically
"Growth hormone opens the door of hope for older women, but the indications need to be strictly screened."-- Professor Tian Li, Peking University People's Hospital
Notes:
·Taboo population: Use caution in patients with diabetes, insulin resistance, and tumors
·Combination therapy: GH needs to be combined with antioxidants such as coenzyme Q10 and vitamin E to synergistically improve mitochondrial function
Growth hormone provides a molecular solution for improving egg quality, especially allowing older women to see the possibility of "winning with quality". However, individual responses vary significantly, and personalized plans need to be formulated under the guidance of reproductive doctors. After all, the key to the test tube black box will eventually belong to the symbiosis of science and persistence.